- Updated: March 11, 2026
- 1 min read
Stanford Researchers Unveil Universal Intranasal Vaccine Offering Broad Respiratory Protection
Stanford Researchers Unveil Universal Intranasal Vaccine Offering Broad Respiratory Protection
Stanford Medicine researchers have announced a breakthrough intranasal vaccine (GLA‑3M‑052‑LS+OVA) that elicits durable innate and adaptive immunity in mice. The vaccine provides months‑long protection against a wide spectrum of respiratory threats—including SARS‑CoV‑2, other viral pathogens, bacterial infections, and even allergens—suggesting a path toward a universal respiratory vaccine.
The study demonstrated that a single dose of the vaccine generated strong mucosal immune responses, reducing viral load and preventing disease symptoms when mice were later exposed to different respiratory viruses and bacterial agents. Importantly, the protection persisted for several months, highlighting the vaccine’s potential for long‑term immunity.
Stanford scientists emphasize that the platform could be rapidly adapted to emerging pathogens, offering a versatile tool for future pandemic preparedness. The findings are detailed in a recent Stanford Medicine news release.
Read the full original article on Stanford Medicine’s website: Universal Vaccine Breakthrough.
Explore related topics on ubos.tech: Universal Vaccine Research, Respiratory Immunity Advances.
Andrii Bidochko
CTO UBOS
Andrii Bidochko is an AI entrepreneur and researcher focused on AI agents, reinforcement learning, and autonomous systems. He writes about the technologies shaping the future of machine intelligence, from frontier models and agent architectures to real-world AI applications.